What Is Tumor/Tissue-Agnostic Therapy? FDA-Approved Biomarkers

What Is Tumor/Tissue-Agnostic Therapy?

Tumor/tissue-agnostic therapy is a targeted treatment approach based on a tumor’s molecular biomarkers , regardless of the tissue or organ where the cancer arose. This next-generation approach personalizes treatment plans by focusing on “how” cancer develops rather than “where.” Thus, the detection of the same genetic mutation in one patient’s lung cancer and another patient’s colon cancer may allow the same targeted drug to be used in both patients.

In this respect, it differs from conventional treatment paradigms based on cancer type and points toward even more individualized medicine in the future.

How Does It Differ From Conventional Cancer Treatments?

In traditional treatment models, diseases are classified by the organ where they arise: for example, “stage 4 pancreatic cancer” or “metastatic breast cancer.” Advances in genetic analysis technologies, however, have shown that two patients with the same diagnosis may have entirely different molecular profiles.

The tumor/tissue-agnostic approach places these biological differences at its center. It therefore offers treatment options independent of the cancer’s histological classification , personalized to the patient’s molecular profile. This approach:

• May offer a high chance of successful treatment response,
• May avoid unnecessary chemotherapy or immunotherapy,
• May improve treatment efficacy while reducing toxicity.

How Does the Tumor/Tissue-Agnostic Approach Work?

This treatment model is based on advanced molecular diagnostic technologies such as next-generation sequencing (NGS) . Genetic material obtained from the patient’s tumor tissue or blood is analyzed to identify specific biomarkers (mutations, gene fusions, etc.). Treatment is planned using targeted drugs developed against these markers.

The process generally involves the following steps:

1. Molecular Testing: A sample is obtained from tumor tissue or a liquid biopsy.
2. Genetic Profiling: Patient-specific mutations are identified using NGS or similar technologies.
3. Biomarker Identification: The focus is on specific mutations (e.g., NTRK fusion, BRAF V600E).
4. Drug Matching: Available approved drugs or drugs in clinical trials are identified.

For example, an NTRK gene fusion may occur in different tumor types, such as thyroid cancer and sarcoma. Once detected, an approved NTRK inhibitor can be used regardless of the tissue.

FDA-Approved Tumor/Tissue-Agnostic Biomarkers and Treatments

Since 2017, the FDA has granted “tumor/tissue-agnostic” approvals for drugs that can be used according to a cancer’s molecular biomarkers. These approvals have opened new doors of hope, particularly for patients with rare mutations. The table below covers approved treatments in this field and the biomarkers they target:

Timeline by year of drugs approved by the FDA for tissue-agnostic use. This chart shows the chronological progression of therapeutic advances.

Who Can Benefit From These Treatments?

Tumor/tissue-agnostic therapies are not universal solutions applicable to every patient. However, they can make a major difference in certain situations:

• People with treatment-resistant or metastatic tumors may benefit
• Patients who do not respond to standard treatments or have exhausted numerous treatment options
• Patients with rare mutations who are not suitable for conventional treatment
• Particularly, people who underwent molecular profiling at an early stage of diagnosis may benefit

The basic requirement for benefiting from these treatments is accurate and timely genetic analysis.

Frequency of tissue-agnostic biomarkers in different organs and cancer types. These data reveal which cancers make genetic testing particularly important.

The Role of Genetic and Molecular Tests

Identifying the right biomarkers is essential for implementing tumor/tissue-agnostic therapies. The main molecular tests used for this purpose are:

• NGS (Next-Generation Sequencing): Comprehensive genetic analysis
• FISH (Fluorescent In Situ Hybridization): Detection of gene fusions
• PCR (Polymerase Chain Reaction): Targeting specific mutations
• IHC (Immunohistochemistry): Biomarker detection at the protein level

These tests can be performed on a tissue biopsy or a liquid biopsy (blood sample). In Türkiye, private laboratories and some university hospitals offer this service.

Advantages and Limitations

Advantages:

• Individualized treatment: An approach tailored to each patient’s genetic makeup
• Use independent of cancer type: The tumor’s biology matters, rather than its location
• Higher response rates and potentially longer survival

Limitations:

• High testing costs and drugs outside SGK reimbursement coverage
• Rare biomarkers make finding eligible patients difficult
• Drug access: Not every FDA-approved drug may be available in Türkiye

Clinical Use in Türkiye and Worldwide

Genetic profiling has become routine at many centers in the US and Europe. In Türkiye, the number of centers offering these tests is increasing, but tests and drugs outside the reimbursement system create access challenges. Private insurance and patient support programs are important in this area.

Looking Ahead: The Potential Expansion of Tumor-Agnostic Therapies

Scientific advances suggest that this field will expand further in the future:

• Multiomics approaches: Fields such as genomics, transcriptomics, proteomics and epigenetics will be integrated
• AI-assisted drug matching: Real-time treatment recommendations based on the patient’s profile
• Combination therapies: More effective results will be achieved by targeting multiple mutations
• Use in early diagnosis: These treatments may be much more effective when given in early-stage rather than advanced disease

Conclusion

Tumor/tissue-agnostic therapy is opening the door to a fundamental paradigm shift in oncology. By targeting the disease’s molecular dynamics rather than its origin, this approach both improves treatment success and moves medicine toward greater individuality and precision. However, continued progress in this field requires access to testing, data integrity, cost management and national health policies to adapt to this change.